Recent News
A current review of eosinophilic granulomatosis with polyangiitis (EGPA) provides current recommendations on diagnosis and management.Read Article
ICYMI: VEXAS Syndrome - A Review
Beck et al has published a review of the VEXAS syndrome in The Lancet, focusing on the pathogenesis, spectrum, and treatment strategies.
Read Article
EULAR26: GLP-1 Agonist Use in the RISE Registry
EurekAlert!
At EULAR 2026, McCormick and Curtis et al presented data from the American College of Rheumatology’s (ACR) Rheumatology Informatics System for Effectiveness (RISE) registry on the use of GLP-1 agents in rheumatic diseases (RMD).
Read Article
ICYMI: Glucocorticoid Injections in Knee Osteoarthritis
A randomized clinical trial of 60 patients found that glucocorticoid injections into the infrapatellar fat pad (IPFP) did not significantly reduce pain scores in patients with inflammatory knee osteoarthritis (compared to placebo).
Read Article
Spotlight on Comorbidities from EULAR 2026
EurekAlert!
Systemic autoimmune diseases are associated with increased cardiovascular morbidity and mortality – possibly through autonomic imbalance, myocardial inflammation, or fibrotic infiltration of the conduction system. A team in Colombia have been looking into the risk of cardiac arrhythmias and conduction disorders in adults with systemic autoimmune diseases compared with the general population – with the aim of
Read Article
My take on diet based intervention studies presented at #EULAR2026
It's all in the title: Diet as a DMARD? The Evidence Is Still Hard to Swallow
https://t.co/JDVlaOsC6w
Head to @RheumNow.com to have a read and for more faculty articles! https://t.co/luV3zZTKOU https://t.co/xHq23oYpjY
Dr. John Cush @RheumNow ( View Tweet)
An IL-23i through ~5 years: How did clinical manifestations of PsA and radiographic progression change during long-term treatment?
🔥View the latest long-term data from ACR to find out more. Sponsored by AbbVie Medical Affairs + Health Impact.
https://t.co/KfkpMpciEf https://t.co/As0CyHDP8p
Dr. John Cush @RheumNow ( View Tweet)
Is it all over for avacopan? #Vasculitis
https://t.co/1sFUidC6Cw
Rheuma Doc @LastManStand85 ( View Tweet)
RT @jiharheum : ETA+MTX vs triple therapy after MTX failure in #RA: machine learning-emulated RACAT trial (n=3,472 VA pts) confirms ETA+MTX modestly better overall. But smoking matters: benefit disappears in current smokers. Precision medicine from RWD. #EULAR2026 POS0255
Dr. John Cush @RheumNow ( View Tweet)
RT @drminidey
#OP0208 #EULAR2026: phase 3 COURAGE-RA trial showed strong efficacy for selective JAK1 inhibitor zemprocitinib in D2T RA after bDMARD failure. Responses were rapid (from week 2), sustained through week 24 and achieved with a reassuring safety profile.
Dr. John Cush @RheumNow ( View Tweet)
Which is NOT a key feature of inflammatory back pain: relief with activity; morning stiffness; age under 40 years; unilateral pain? Test your knowledge in this week's RheumIQ quiz at https://t.co/z8mLbcgE5D. https://t.co/tOdPfEBJa4
Dr. John Cush @RheumNow ( View Tweet)
Obexelimab in IgG4-Related Disease: INDIGO Trial
Dr. Henrique Dalmolin reports on abstract OP018 from EULAR 2026.
https://t.co/Wid9ZzESae https://t.co/Qo4y8ebkOn
Dr. John Cush @RheumNow ( View Tweet)
ICYMI: 2025 Update: EULAR Recommendations on Rheumatoid Arthritis Management
The European Alliance of Associations for Rheumatology (EULAR) has updated their rheumatoid arthritis (RA) management recommendations, notably with fewer recommendations (total of 9, down from 11 in 2022 version), by merging and removing previous recommendations.
Read Article
ICYMI: B Cells at the Brink in Sjögren Disease
A recent issue of Arthritis & Rheumatology reviews current understanding of the immunopathogenesis of Sjögren disease (SjD) and how that has influenced the quest for drug development for this most systemic autoimmune disorder.
Read Article
EULAR26: Reports on Systemic Sclerosis
EurekAlert!
In an oral abstract presentation at EULAR 2026, results were shared from a longitudinal observational analysis of the EUSTAR database. The aim was to characterise organ involvement and disease progression – and time to these events – stratified by having a modified disease activity index (mDAI) score of less than 2.5 at baseline (inactive), versus those with 2.5 or higher (active).
Read Article
2026 Guidelines for the Treatment of Axial Spondyloarthritis
New guidelines offer clinicians and patients clearer directions on diagnostic workup, treatment selection, and long-term disease management, while emphasizing shared decision-making due to ongoing evidence gap. https://t.co/SUFnOMAUw8
Dr. John Cush @RheumNow ( View Tweet)
Self-Directed Cognitive Behavioral Therapy for Chronic Pain
Is self-directed cognitive behavioral therapy (CBT) when augmented with asynchronous, personalized feedback for chronic pain (CBT-CP) superior to clinician-delivered CBT-CP?
https://t.co/P2DDvCiLNL https://t.co/hyAArEG6V1
Dr. John Cush @RheumNow ( View Tweet)
EULAR26: Pitfalls in T2T
EULAR recommends T2T strategy in the management of RA and other RMD aiming for clinical remission or low disease activity guided by frequent monitoring and prompt therapy adjustments. But real-world daily implementation in remains poorly investigated. https://t.co/V6mCcdmyJz
Dr. John Cush @RheumNow ( View Tweet)
2-Gene Blood Test for Kawasaki Disease in Febrile Children
JAMA Network Open has publshed that a simple 2-gene blood test may aid the earlier diagnosis of Kawasaki disease in children with febrile illnesses.
https://t.co/Pwb23fOcO9 https://t.co/P6g23uJzNb
Dr. John Cush @RheumNow ( View Tweet)
True or False: A 5-year retrospective study found that platelet-rich plasma injections significantly outperformed NSAIDs when given to early knee osteoarthritis patients. See if you got it right in this week's RheumIQ quiz at https://t.co/Z8XFynKJ0o. https://t.co/Eu82fctE4B
Dr. John Cush @RheumNow ( View Tweet)
Video
From the Blog
Podcasts
Generic Tofacitinib (6.26.2026)
DERM on RheumNow (June 2026)-
Do You Zoster Vaccinate? (6.19.2026)
RheumNow EULAR 2026 Rheumatology Round Up
Therapeutic Updates
Psoriatic arthritis and overweight or obesity
Sponsored by Lilly Medical Affairs
Dr. Merola presenting the results from TOGETHER‑PsA, a phase 3b trial evaluating the concomitant use of an IL‑17A antagonist and an incretin receptor agonist in adults with psoriatic arthritis and overweight or obesity.
Read Post
Poster Hall
Sponsored by AbbVie Medical Affairs + Health Impact
